For research use only. Not for therapeutic Use.
ChloroquineD5（Cat No.:I014825） is a deuterated form of Chloroquine, an antimalarial and anti-inflammatory agent. Chloroquine has been extensively studied in the context of malaria and rheumatoid arthritis. It acts as an inhibitor of autophagy and toll-like receptors (TLRs). Notably, Chloroquine exhibits efficacy in inhibiting SARS-CoV-2 (COVID-19) infection, with an EC50 value of 1.13 μM. This finding has generated interest in exploring Chloroquine as a potential therapeutic option for COVID-19.
| Catalog Number | I014825 |
| CAS Number | 1854126-41-2 |
| Molecular Formula | C₁₈H₂₁D₅ClN₃ |
| Purity | ≥95% |
| Target | Autophagy |
| Storage | Store at -20°C |
| IUPAC Name | 4-N-(7-chloroquinolin-4-yl)-1-N-ethyl-1-N-(1,1,2,2,2-pentadeuterioethyl)pentane-1,4-diamine |
| InChI | InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)/i1D3,4D2 |
| InChIKey | WHTVZRBIWZFKQO-SGEUAGPISA-N |
| SMILES | CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl |
| Reference | [1]. Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43.<br>[2]. Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665-1672.<br>[3]. Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626.<br>[4]. Colson P, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.<br>[5]. Savarino A, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20(3):131-135. |
